A BMI below 27 does not exclude the liver disease MASH. A new analysis of the ESSENCE trial focuses on adults in that weight range who already had biopsy-defined disease and moderate or advanced liver scarring. It offers encouraging signals, but leaves important questions about treatment effects in this smaller group.
In its November 8 announcement, Novo Nordisk reported liver-marker results for 106 participants with BMI below 27, drawn from the trial’s first 800 participants. The exploratory analysis was presented at The Liver Meeting 2026. Its most useful message for readers is about interpreting liver evidence beyond a weight category—not a new reason to seek weight-loss medication.
Who was actually studied?
ESSENCE enrolled adults with metabolic dysfunction-associated steatohepatitis, or MASH, and stage F2 or F3 fibrosis. The trial registry required liver-biopsy evidence and an age of at least 18. These were people with established liver disease, rather than a general population selected because of BMI.
The subgroup’s “below 27” boundary should not be translated into “all normal weight.” The announcement does not provide the full BMI distribution or diabetes breakdown for these 106 adults. It also cannot tell us whether people with a lower BMI benefit more or less than those with a higher BMI. Our guide to BMI and health explains why a weight category is only one part of a health assessment.
What changed at 72 weeks?
The research compared once-weekly semaglutide 2.4 mg injection with placebo. That describes the studied regimen, not a dosing instruction. Novo’s reported subgroup table gives estimated treatment ratios for some measures and estimated differences for others:
| Measure | Estimated effect (95% confidence interval) |
|---|---|
| ALT liver enzyme | Ratio 0.61 (0.48–0.79) |
| AST liver enzyme | Ratio 0.67 (0.56–0.80) |
| FAST disease-activity score | Difference −0.13 (−0.26 to −0.01) |
| ELF fibrosis score | Difference −0.45 (−0.73 to −0.17) |
| PRO-C3 collagen-formation marker | Ratio 0.82 (0.71–0.95) |
| VCTE liver-stiffness measurement | Ratio 0.88 (0.73–1.06) |
Ratios below 1 and differences below zero favor semaglutide in this table. A ratio of 0.61 is a comparison with placebo; it is not a claim that scarring fell by 39%, or that 61% of participants improved. The liver-stiffness confidence interval includes 1, so that result remains compatible with no difference between groups.
ALT and AST are markers of liver injury; they do not directly measure scar tissue. The fibrosis-related markers add information, but their changes cannot be read as percentages of scarring reversed. None of these figures establishes fewer liver complications.
Why the larger trial cannot fill every subgroup gap
The original ESSENCE abstract reports a planned 72-week analysis of 800 participants. Fibrosis improvement without worsening steatohepatitis occurred in 36.8% with semaglutide versus 22.4% with placebo. Those are results for the overall interim population, not response rates for the 106-person subgroup.
The new announcement says subgroup histology findings were also reported, but does not supply their numerical response rates. We therefore cannot use the larger trial’s percentages to answer how many lower-BMI participants had biopsy-confirmed improvement.
Randomization strengthens the parent trial, while this later subgroup examination remains exploratory. The release does not describe the subgroup’s missing-data handling, treatment-discontinuation strategy, per-arm numbers or adjustment for testing multiple markers. It does not identify enough analysis detail to classify these estimates as treatment-regimen or efficacy results. Our guide to reading trial results explains why denominators and analysis methods matter.
Longer follow-up also remains unfinished. The ESSENCE registry lists cirrhosis-free survival at 240 weeks as a further primary outcome and records the trial as active, not recruiting. A biomarker presentation is not that clinical-outcome result.
A liver indication is different from weight-management eligibility
The FDA-hosted prescribing information already includes Wegovy injection for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with F2–F3. That indication does not specify a minimum BMI. It has accelerated approval based on MASH and fibrosis improvement; continued approval may depend on confirming clinical benefit. The November presentation is additional evidence, not a new approval.
This distinction matters when reading a headline about BMI below 27: evidence for a defined liver condition does not establish general weight-management eligibility at that BMI. The semaglutide profile provides broader medicine context.
Safety still requires individual clinical assessment. The current US label describes gastrointestinal adverse effects and a boxed warning about thyroid C-cell tumors in rodents, with uncertain human relevance. It contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. The subgroup announcement supplies no detailed subgroup safety table.
Questions worth taking to an appointment
For someone already discussing liver disease, useful questions are what established the diagnosis and fibrosis stage, which tests track injury versus scarring, and what uncertainty remains about long-term benefit. A lower BMI alone answers none of those questions. Our appointment guide can help organize the conversation.
This explainer draws on the sponsor announcement, original trial abstract, registry and approved labels. The full subgroup presentation, full trial paper and supplement were not inspected. Fuller subgroup methods, safety findings and clinical outcomes would make the next evidence update more informative.



